Cartalax

What is Cartalax? Definition and basics of the cartilage peptide

Cartalax (also known as T-31 or AC-4) is a synthetic tripeptide built from the amino acids alanine, glutamic acid, and aspartic acid (AED). It was developed as a tissue-specific peptide bioregulator for cartilage tissue. The substance comes from Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology [3]. Bioregulators are ultra-short peptide chains that are thought to act as targeted signaling agents for specific tissue types in the body.

The biological idea behind Cartalax comes from the AED sequence, which occurs naturally in the structural protein collagen type XI. The peptide is thought to directly stimulate chondrocytes (cartilage cells) to regenerate and support tissue integrity. Scientific confirmation of this cellular signaling effect in humans is still pending.

How is Cartalax used? An overview of the available forms

In practice, Cartalax comes in two forms: oral capsules as a dietary supplement and experimental injectable preparations. Neither route has official drug approval.

• Oral capsules (Russia): Khavinson peptide bioregulators are sold in Russia as dietary supplements, typically with 20 mg of peptide per capsule - without controlled clinical studies on their effectiveness in humans.
• Injectable lyophilisate (international gray market): On the international research peptide market, Cartalax is offered as a freeze-dried powder in vials for subcutaneous injection after reconstitution. This is an unproven user practice without medical approval.

For both forms, there is no validated human dose: the oral 20 mg amount comes from unregulated supplement practice, while the injected 1-2 mg is based on estimates from user forums. For further technical basics on handling vials and storage conditions, see our step-by-step guides, though no evidence-based protocol exists for Cartalax.

From vial to use: How is Cartalax dosed in practice?

In non-clinical user practice, a gray-market vial with 10 mg of lyophilized Cartalax is typically reconstituted with 2 ml of BAC water, resulting in a calculated final concentration of 5 mg of peptide per milliliter. This reconstitution is unproven user practice, not a validated protocol.

Using a standard insulin syringe with 100 units (1 ml total volume), one tick mark of 0.1 ml (10 units) corresponds to 0.5 mg of Cartalax. The doses of 1 to 2 mg per administration mentioned in user reports therefore correspond to an injection volume of 0.2 to 0.4 ml of this solution.

This model calculation only documents the practice commonly used in forums, without medical validation. There is no clinical evidence that the mentioned amounts are safe or effective. Since no clinical evidence exists for Cartalax regarding safety, purity, or efficacy, Cartalax is not approved as a medication, and the purity of gray-market preparations is not tested. Before obtaining it through unofficial sources, you should check the risks in the Vendor Radar for peptide safety.

How does Cartalax work? The mechanism of peptide bioregulators

Cartalax differs fundamentally from classic peptides like semaglutide or BPC-157: it does not primarily bind to cell surface receptors. Instead, due to its low molecular mass of about 333 g/mol, it is thought to diffuse directly into the cell nucleus.

Inside the nucleus, the tripeptide is thought to interact directly with the chromatin structure of DNA and epigenetically stimulate the transcription of cartilage-specific genes [1][3]. The scientific hypothesis is that genes for structural proteins are upregulated, while inflammatory and degradative processes in cartilage tissue are inhibited.

This epigenetic mechanism of Cartalax has so far only been observed in in-vitro cell cultures; proof of these signaling pathways in the human body is still lacking.

What does the research on Cartalax show? Study situation and evidence

The scientific study situation on Cartalax is entirely limited to preclinical in-vitro and animal models; published clinical studies in humans are missing.

The cell study by Ashapkin et al. (2020) shows that the AED amino acid sequence measurably influences the gene expression of repair pathways in human mesenchymal stem cells [1]. However, this laboratory finding does not provide scientific proof of biological activity when taken systemically or injected in humans.

In the animal study by Khavinson et al. (PMID 18306703), the peptide T-31 increased bone density and stabilized cartilage structures in ovariectomized rats [2]. Due to species-specific metabolic differences, these animal doses cannot be directly transferred to humans.

Are there risks and side effects with Cartalax?

The side effect profile and toxicology of Cartalax are insufficiently researched in humans, as standardized clinical safety tests and phase studies are lacking.

• Immune reactions: The synthetic peptide could potentially trigger the formation of antibodies or allergic reactions, though their frequency is unclear due to a lack of studies.
• Unknown interactions: Possible interactions of Cartalax with established medications have not been scientifically investigated.
• Gray market risks: Non-certified preparations carry risks regarding contaminants, unclear peptide identity, and microbial contamination with injections.
• Missing long-term data: There are no long-term observations on the safety of repeated or prolonged oral and parenteral use.

Since Khavinson peptides are only registered as dietary supplements in Russia, the proof of therapeutic safety and pharmaceutical quality required for regular medications is not applicable.

How does Cartalax differ from other peptides?

Cartalax differs from more established research peptides like BPC-157 primarily through its hypothetical intervention in gene expression in the cell nucleus, as well as a significantly smaller preclinical data basis. BPC-157 also has no human approval, but it has considerably more preclinical data and a larger community experience base. For a systematic comparison of various tissue and regeneration peptides, see the peptide library overview.

While standard peptides activate membrane-bound receptors, the bioregulator approach of Cartalax targets direct DNA interactions - a mechanism with high theoretical specificity, but minimal clinical validation so far.

Conclusion: Scientific assessment of Cartalax

Cartalax represents an interesting theoretical approach from Russian bioregulator research, which aims to specifically influence cartilage and bone cells via the AED sequence. Despite plausible preclinical data on gene expression and bone density in animal models, human studies, standardized dosages, and safety evidence for use in humans are completely lacking.